SXTP 60 Degrees Pharmaceuticals
- 0.275
- +0.002+0.77%
60 Degrees Pharmaceuticals News
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersSharps Technology (NASDAQ:STSS) stock rose 140.0% to $0.51 during Tuesday's regular session. The company's market cap stands at $8.0 million. Insmed (NASDAQ:INSM) stock moved upwards by 112.72%
12 Health Care Stocks Moving In Friday's After-Market Session
GainersSharps Technology (NASDAQ:STSS) shares rose 50.5% to $0.32 during Friday's after-market session. The market value of their outstanding shares is at $5.0 million. Cyclacel Pharmaceuticals (NASDA
Analysts' Opinions Are Mixed on These Healthcare Stocks: 60 Degrees Pharmaceuticals, Inc. (SXTP), GoodRx Holdings (GDRX) and Dianthus Therapeutics (DNTH)
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersSINTX Techs (NASDAQ:SINT) shares increased by 22.2% to $0.16 during Wednesday's after-market session. The company's market cap stands at $19.1 million. As per the news, the Q1 earnings report c
Express News | 60 Degrees Q1 EPS $0.03 Up From $(1.13) YoY, Sales $80.66K Up From $(51.66K) YoY
Express News | 60 Degrees Pharmaceuticals- Qtrly Shr $0.03
60 Degrees Pharm 1Q Rev $105.7M >SXTP
60 Degrees Pharm 1Q Rev $105.7M >SXTP
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) reported today their financial results for the first fiscal quarter of the 2024 year, ended March 31, 2024.
10-Q: Quarterly report
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 55.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $251.8 million. MiNK Therapeutics (NASDAQ:INK
Express News | 60 Degrees Pharmaceuticals Announces Publication Of Better Titled 'Trial Planned to Evaluate Safety and Efficacy of Tafenoquine + Atovaquone/Azithromycin in Hospitalized Babesiosis Patients' In The Journal of Infectious Diseases
Express News | 60 Degrees Pharmaceuticals Inc - Enrollment for Babesiosis Trial Set for Summer 2024
Express News | 60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
60 Degrees Pharmaceuticals, Inc. (SXTP) Receives a Hold From H.C. Wainwright
Express News | 60 Degrees Pharmaceuticals Receives FDA Comments On Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required, Trial Planning And Execution To Proceed As Planned
Express News | 60 Degrees Pharmaceuticals Inc - Is Continuing Preparatory Actions to Facilitate Initiation of Patient Enrollment Later in 2024
Express News | 60 Degrees Pharmaceuticals Inc: FDA Had Some Questions and Recommendations That Will Be Addressed
Express News | 60 Degrees Pharmaceuticals Inc: Trial Planning and Execution to Proceed as Planned
Express News | 60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
Express News | 60 Degrees Pharmaceuticals Announced That It Will Sponsor A Pilot Study Of Tafenoquine, The Active Molecule In Its U.s. Food And Drug Administration (Fda)-approved Human Malaria Prevention Medication, Arakoda, For The Treatment Of Babesiosis In Dogs
Analysis
Price Target
No Data
